ea0032p473 | Diabetes | ECE2013
Zavattaro Marco
, Prodam Flavia
, Grazia Mauri Maria
, Pagano Loredana
, Caputo Marina
, Belcastro Sara
, Allochis Gabriele
, Aimaretti Gianluca
Introduction: Liraglutide, a human GLP-1 analogue, is a new option for the treatment of type 2 diabetes (DM2). The purpose of this study was to evaluate the effects of liraglutide on cardiovascular risk factors in daily clinical practice in a heterogeneous population with DM2.Subjects and methods: Four visits were scheduled in a 1 year study (baseline, 4, 8 and 12 months). Patients with a HbA1c not on target (>7%) during an oral hypoglycemic treatmen...